<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889706</url>
  </required_header>
  <id_info>
    <org_study_id>MTiT1DM</org_study_id>
    <nct_id>NCT01889706</nct_id>
  </id_info>
  <brief_title>Metformin Therapy in Type 1 Diabetes Mellitus.</brief_title>
  <official_title>Application of Metformin as Adjuvant Therapy in Overweight and Obese Patients With Type 1 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of exogenous insulin and incorrect nutritional habits are conducive to obesity and&#xD;
      excess weight. This leads to the development of insulin resistance, even in patients with&#xD;
      type 1 diabetes mellitus. The purpose of this study is to assess the effects of metformin as&#xD;
      adjunctive therapy on anthropometric parameters, insulin resistance and metabolic control in&#xD;
      overweight and obese patients with type 1 diabetes mellitus.&#xD;
&#xD;
      The study group consists of 200 Caucasian type 1 diabetic patients with elevated adipose&#xD;
      tissue content as measured by electrical bioimpedance, treated at the Poznan University of&#xD;
      Medical Sciences Department of Diabetology in 2009-2014. All patients have type 1 diabetes&#xD;
      diagnosed by autoimmune antibodies, and are treated with intensive insulin therapy. This&#xD;
      group is divided into metformin treated arm (group I+ M, 100 subjects), the remaining 100&#xD;
      patients are treated with insulin alone (control group, group I). Metformin is administered&#xD;
      at least 6 months at a mean dose of 1000 mg/day.&#xD;
&#xD;
      The investigators would like to assess the impact of metformin treatment on metabolic&#xD;
      control, insulin resistance and anthropometric parameters in overweight and obese patients&#xD;
      with type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Body fat content and anthropometric parameters</measure>
    <time_frame>6 months</time_frame>
    <description>assessed by electrical bioimpedance using a Tanita BC-418 MA device,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of metabolic control</measure>
    <time_frame>6 months</time_frame>
    <description>(HbA1C, lipid profile)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin requirement</measure>
    <time_frame>3 , 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of skin AGE</measure>
    <time_frame>6 months</time_frame>
    <description>AGE-Reader ( Diagn-Optic)</description>
  </other_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Loss of Control of Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        200 Caucasian patients with type 1 diabetes admitted to the Department of Internal Medicine&#xD;
        and Diabetology, Poznan University of Medical Sciences in years 2009-2014, treated with&#xD;
        intensive insulintherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 years &lt;60 years,&#xD;
&#xD;
          -  duration of diabetes &gt;3 years,&#xD;
&#xD;
          -  lack of metabolic control- HbA1C&gt;7,5% (despite participation in 5-day WHO education&#xD;
             program)&#xD;
&#xD;
          -  treated with intensive insulin therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metabolically decompensate diabetes with acetonuria,&#xD;
&#xD;
          -  suspected lack of compliance,&#xD;
&#xD;
          -  lack of glucose and ketones self-monitoring,&#xD;
&#xD;
          -  hypoglycaemic unawareness or recurrent severe hypoglycemia (defined as more than two&#xD;
             episodes of hypoglycemia lowered than 60 mg/dl with loss of consciousness, required&#xD;
             assistance to treat) in the past 3 months,&#xD;
&#xD;
          -  recurrent diabetic ketoacidosis (more than two episodes in the past year)&#xD;
&#xD;
          -  another serious medical illness,&#xD;
&#xD;
          -  pregnancy or sexually active woman unwilling to take birth control.&#xD;
&#xD;
          -  renal impairment (estimated on the value calculated glomerular filtration rate using&#xD;
             the MDRD formula-estimated glomerular filtration rate, eGFR&lt;45 mL / min&#xD;
&#xD;
          -  liver cell damage Alanine aminotransferase (ALT), Aspartate aminotransferase (AST)&#xD;
             greater than twice the upper normal limit),&#xD;
&#xD;
          -  history of drug or alcohol abuse or those who used this drug before&#xD;
&#xD;
          -  changes in the way of antihypertensive and antihyperlipemic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariusz Naskręt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznań University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine and Diabetology, Raszeja Hospital</name>
      <address>
        <city>Poznan</city>
        <state>Great Poland</state>
        <zip>60-834</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Zawada, MD</last_name>
      <email>aga.zawada@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Agnieszka Zawada</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Type 1 diabetes mellitus,</keyword>
  <keyword>metformin,</keyword>
  <keyword>insulin resistance,</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

